News briefing: Amarin's panel could put Vascepa patents in jeopardy; Santhera nabs a Duchenne drug
Amarin’s fish oil empire may be slipping out of its grasp.
On Wednesday, in the latest twist in a long legal battle, the appeal panel of judges was announced for the patent dispute between Amarin with two generic drugmakers that are looking to make off-brand decision. No ruling has yet been made — the hearing starts at 10:30 this morning — but analysts believed that the decision could come down to which judges were chosen, and that these judges may be unlikely to decide in Amarin’s favor. The stock fell 17% pre-market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.